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Background.Gestational diabetes (GDM) affects up to 7% of pregnant women and is associated with several maternal and perinatal
morbidities. International organizations suggest several different recommendations regarding how to screen and to manage GDM.
Objective. We aimed to analyze the most important and employed guidelines about screening and management of GDM and we
investigated existing related literature. Results. We found several different criteria for screening for GDM, for monitoring GDM,
and for starting pharmacological therapy. When using IADPSG criteria, GDM rate increased, perinatal outcomes improved, and
screening became cost-effective. Compared to no treatment, treatment of women meeting criteria for GDM by IADPSG criteria
but not by other less strict criteria has limited evidence for an effect on adverse pregnancy outcomes.
1. Introduction
Gestational diabetes (GDM) can be broadly defined as
glucose intolerance during pregnancy that affects women
without previous diagnosis of diabetes or unknown state.
The incidence is about 7% worldwide and this rate has
been growing during the last decades and is estimated to
increase in the future. The most important risk factors are
maternal overweight and obesity, age greater than or equal
to 35 years at delivery, hypertension, metabolic syndrome,
nonwhite ethnicity, family history of diabetes mellitus, prior
unexplained stillbirth, prior infant with congenital anomaly
(if not screened during that pregnancy), prior macrosomic
infant, history of gestational diabetes, chronic use of steroids,
glycosuria, and known impaired glucose metabolism [1].
The importance of GDM is linked to the consequences
of pregnancy and also after pregnancy to both mother and
newborn. Hyperglycemia in the mother causes abnormal
metabolism while in the fetus it causes hyperinsulinemia and
its consequences, and incidence of complications is inversely
proportional to glucose control. Macrosomia, polyhydram-
nios, operative delivery, shoulder dystocia, birth injury,
perinatal mortality, hypertensive disorders and preeclampsia,
congenital malformations (OR: 1.2–1.4), and risk of cesarean
delivery are higher in women with GDM; in the long term,
women with GDM have a higher risk of developing type
2 diabetes mellitus and cardiovascular diseases; long-term
sequelae for offspring are obesity and metabolic syndrome.
Approximately 50% of women identified as having GDMwill
develop frank diabetes within 10 years [2].
To prevent or decrease the risk of GDM, weight loss
before pregnancy and cardiovascular exercise could be useful.
In fact, aerobic exercise for 35–90 minutes 3-4 times per
week during pregnancy is associated with a significantly
higher incidence of vaginal delivery and a significantly lower
incidence of cesarean delivery, with a significantly lower
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incidence of gestational diabetes mellitus and hypertensive
disorders [3]. Prompt diagnosis and management are impor-
tant to reduce worse pregnancy outcomes.
Nonetheless, screening, management, and follow-up of
GDM are controversial on international organizations rec-
ommendations.
2. Screening Controversies
The aim of screening is to identify asymptomatic pregnant
women at high risk of developing GDM. Screening appears
to be cost-effective for prevention of obstetrical adverse
outcomes and long-term consequences of GDM [4].
Regarding the effect of screening [1] on obstetrical out-
comes, there are many controversies:
(a) Indications for screening (who): universal versus
selective screening
(b) Timing of screening (when): early screening versus at
24–28 weeks
(c) Type of screening (how): One- versus Two-Step
(d) Criteria for diagnosis: recommendations of interna-
tional organizations are not standardized
(a) The population to screen has not been uniformly
identified. There are two possible approaches.
(i) Selective Screening. Only women with risk factor for GDM
are offered to be screened, that is, age > 25 years; ethnic origin
Hispanic, African, Native American, South or East Asian,
or Pacific Islander; BMI > 25; previous personal or family
history of impaired glucose tolerance; or history of adverse
obstetric outcomes associated with GDM.
(ii) Universal Screening. All women are subjected to screening;
in developed countries where overweight and obesity are
widespread health problems, this could be the best choice to
avoid undiagnosed GDM.
Universal screening is the most commonly adopted
method in the USA, while in other countries such as Italy the
selective approach is preferred [5].
(b) When identifying the population, it is essential to
decide the right time to screen.
Women with risk factors and high suspicion of undiag-
nosed type 2 DM (i.e., obesity, metabolic syndrome) should
be screened before pregnancy or at the first prenatal visit
(early screening). About 5–10% of women with risk factors
have early GDM, and these represent 40% of all women with
GDM.
In the absence of early screening or for women negative
to early screen, universal screening should be performed at
24 to 28 weeks.
(c) Now we discuss how to screen.
Screening for GDM is somewhat controversial and can
be performed either with a One-Step or with a Two-Step
approach.
(i) One-Step Approach. GDM screening is performed as an
oral 75 g glucose load followed by glucose blood measure-
ment 1 and 2 hours later. A positive result is defined as one
value higher than target values. This approach is based on
HAPO study [6] and is suggested by IADPSG [7], WHO [8],
FIGO [5], and ADA [9]. In fact, HAPO study in 2008 demon-
strated a direct correlation between maternal glucose levels
and increased birth weight and neonatal hyperinsulinemia.
(ii) Two-Step Approach. GDM is performed as a 50 g one-
hour oral glucose load (glucose challenge test, GCT), given
to nonfasting women, with a venous glucose measurement
one hour later. A positive result is defined as a blood glucose
value higher than 130, 135, or 140mg/dL; the most common
value used is 135mg/dL (ACOG) [4]. Positive screening test
is followed by a diagnostic test as an oral glucose tolerance
test (GTT) that consists of a beverage with 100 g of glucose,
with venous glucose measurement at fasting and after 1, 2,
and 3 hours. A positive result is defined as 2 values higher
than target values.
(d) Recommendations of international organizations are
not standardized.
Table 1 shows the different populations and times to
screen and the thresholds used by the most important
international organizations worldwide, updated to the latest
recommendations [4, 5, 8–12].
We found a large number of studies in international
literature comparing One-Step and Two-Step test and differ-
ent glucose thresholds. When evaluating the best screening
method, clinically significant improvements in maternal
and neonatal outcomes were analyzed. Two are the most
significant studies:
(1) Australian Carbohydrate Intolerance Study in Preg-
nant Women (ACHOIS) Trial Group: the aim was to
determine whether treatment of GDM reduced the
risk of perinatal complications.
(2) National Institute of Child Health and HumanDevel-
opment (NICHD) Maternal-Fetal Medicine Units
(MFMU)Network Study: the intent was to determine
whether treatment of womenwithmildGDMreduces
perinatal and obstetrical complications.
Both trials agree with the rule of IADPSG criteria adop-
tion on reducing fetal birth weight over the 90th percentile
and the risk of developing maternal preeclampsia.
Furthermore, to compare the One-Step test to the Two-
Step test, several possible study designs have been evaluated
in the literature. We can summarize the literature in five
groups.
(1) RCTs in which women underwent both the One-Step
and the Two-Step tests and the women positive for the One-
Step but negative for the Two-Step test were randomized to
treatment of GDM versus no treatment: the only such RCT is
byWeiss et al. [12], who unfortunately do not report outcomes
specific to this group of women.
(2) RCTs of treatment versus no treatment of GDM,
focusing on women positive for the One-Step but negative
for the Two-Step test: we found 6 RCTs comparing insulin
or glyburide to placebo or routine care, and all of them
used a Two-Step approach with different glucose thresholds
(Table 2) [13–18]. In this group, ACHOIS trial by Crowther
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Table 1: Criteria for GDM screening and diagnosis.
Population to
screen Time to screen Test
Number of
abnormal
values
required
for
diagnosis
Fasting
glucose
(mg/dL)
1 hour
after
loading
(mg/dL)
2 hours
after
loading
(mg/dL)
3 hours
after
loading
(mg/dL)
ACOG 2013 C&C [4] Selectivescreening First visit
Two-Step, 3 h,
100 g ≥2 95 180 155 140
ACOG 2013 NDDG [4] Selectivescreening First visit
Two-Step, 3 h,
100 g ≥2 105 190 165 145
ADA 2015 [9] Universalscreening 24–28 weeks
One-Step, 2 h,
75 g ≥2 95 180 155
Not
required
ADA 2015 [9] Universalscreening First visit
Two-Step, 3 h,
100 g ≥2 95 180 155 140
ADIPS 2013 [52] Selectivescreening 24–28 weeks
One-Step, 2 h,
75 g ≥1 92 180 153
Not
required
CDA 2013 [10] Universalscreening First visit
Two-Step, 2 h,
75 g ≥2 95 191 160
Not
required
FIGO 2013 [5] Universalscreening 24–28 weeks
One-Step, 2 h,
75 g ≥1 92 180 153
Not
required
IADPSG 2010 [7] Universalscreening 24–28 weeks
One-Step, 2 h,
75 g ≥1 92 180 153
Not
required
NICE 2015 [11] Selectivescreening 24–28 weeks
One-Step, 2 h,
75 g ≥1 101
Not
required 140
Not
required
WHO 2013 [8] Universalscreening 24–28 weeks
One-Step, 2 h,
75 g ≥1 92 180 153
Not
required
ACOG: American College of Obstetricians and Gynecologists; ADA: American Diabetes Association; ADIPS: Australasian Diabetes in Pregnancy Society;
CDA: Canadian Diabetes Association; C&C: Carpenter and Coustan; FIGO: International Federation of Gynecology and Obstetrics; IADPSG: International
Association of Diabetes Pregnancy Study Group; NICE: National Institute for Health and Care Excellence; NDDG: National Diabetes Data Group; WHO:
World Health Organization.
Table 2: RCTs of treatment versus no treatment of GDM, focusing on women positive for the One-Step but negative for the Two-Step test.
Study Screening test Diagnostic test Values fordiagnosis
Intervention
group
Control
group
Primary
outcome
O’Sullivan et al.,
1966 (USA) [13]
50 g GCT: positive
if ≥130mg/dl
100 g, 3 h
(110-170-120-110) 2 or more values Insulin Routine care LGA
Coustan and
Lewis, 1978 (USA)
[14]
50 g GCT: positive
if ≥130mg/dl
100 g, 3 h
(95-180-160-135) 2 or more values Insulin Routine care Macrosomia
Thompson et al.,
1990 (USA) [15]
50 g GCT: positive
if F > 105mg/dL or
1 h > 140mg/dL
100 g, 3 h
(105-190-165-145) 2 or more values Insulin Routine care
Maternal and
neonatal
morbidity
Crowther et al.,
2005 (Australia)
[16]
50 g GCT: positive
if ≥140mg/dl
75 g OGTT
(F > 7.8; 2 h
7.8–10mmol/L)
Both values Insulin Routine care Perinatalcomplications
Landon et al., 2009
(USA) [17]
50 g GCT: positive
if ≥135mg/dl
100 g, 3 h
(95-180-155-140)
2 or more values
but F < 95mg/dL Insulin Routine care
Perinatal
outcome
Casey et al., 2015
(USA) [18]
50 g GCT: positive
if ≥140mg/dL
100 g, 3 h
(105-190-165-145) 2 values Glyburide Placebo Birth weight
et al. [16] is included, mentioned before. The main common
outcome was lower rate of fetal birth weight over the 90th
percentile and macrosomia.
(3) RCTs comparing the One-Step to the Two-Step
methods: we found 3 RCTs by Meltzer et al. [19], Sevket et al.
[20], and Scifres et al. [21] (Table 3). In each one, there are
a study group undergoing One-Step 75 g test and a control
group undergoing Two-Step 100 g test. Regarding GDM rate,
Sevket et al.’s and Scifres et al.’s RCTs reveal an incidencemore
than double in the study group with respect to control group
(14.5% versus 6%; 4.3% versus 0.0%), while in Meltzer et al.’s
RCT, there are no differences (3.6% versus 3.7%). Maternal
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Table 3: RCTs comparing the One-Step to the Two-Step methods.
Author (origin) Study group Control group (1) Control group (2) GDM rate Primary outcome
Meltzer et al., 2010
(Canada) [19] One-Step (2 h, 75 g)
Two-Step (50 g, 1 h;
100 g, 3 h)
Two-Step (50 g, 1 h;
75 g, 3 h)
3.6% versus 3.7%
versus 3.7% Costs of screening
Sevket et al., 2013
(Turkey) [20] One-Step (2 h, 75 g)
Two-Step (50 g, 1 h;
100 g, 3 h) 14.5% versus 6%
Maternal and
neonatal outcomes
Scifres et al., 2014
(USA) [21] One-Step (2 h, 75 g)
Two-Step (50 g, 1 h;
100 g, 3 h) 4.3% versus 0.0%
Maternal and
neonatal outcomes
and neonatal outcomes have been analyzed only in 2 studies.
Sevket et al.’s RCT reveals that GDM-negative women by
IADPSG had better perinatal outcomes than GCT-negative
women and GCT-positive women with a negative OGTT;
Scifres et al.’s RCT concludes that rates of macrosomia,
cesarean delivery, and pregnancy-induced hypertension were
also similar between groups.
Interestingly, Meltzer et al.’s RCT analyzed costs of the
One-Step compared to the Two-Step test: while the Two-Step
test involved the lowest costs, the One-Step test recognized
higher GDM rate.The authors’ conclusion was in favor of the
Two-Step test because the universal glucose screen with 50 g
glucose load is an inexpensive, easy-to-administer tool for
GDM screening, especially with the use of a lower diagnostic
cut-off.
(4) Prospective non-RCTs or retrospective studies com-
paring incidence ofGDMand/or outcomes between theOne-
Step and Two-Stepmethods: we found 9 retrospective studies
comparing the One-Step approach with IADPSG criteria and
Two-Step approach with ACOG criteria (Table 4) [22–30].
Regarding GDM rate, the incidence is higher for women
undergoing the One-Step test in all the studies analyzing this
issue. Only two studies concluded that IADPSG One-Step
approach is useful to avoid worse pregnancy outcomes, in
particular LGA and macrosomia [22, 27], while five studies
did not find statistically significant differences between the
two approaches on outcomes [23–26, 28].
(5) Prospective non-RCTs or retrospective studies report-
ing outcomes of women meeting criteria for GDM based
on the One-Step test but not on the Two-Step test: we
found 8 retrospective cohort studies (Tables 5 and 6) [31–
38], but no study evaluated whether treatment of women
meeting criteria for GDM by IADPSG criteria (One-Step
test) but not by other less strict criteria has an effect on
adverse pregnancy outcomes compared to no treatment.
When analyzing outcomes, macrosomia was more common
in women positive on 75 g IADPSG criteria but negative
on CDA criteria and positive on 75 g IADPSG criteria but
negative on NICE criteria.
3. Conclusion
Despite continuing controversy regarding whether the One-
Step test or the Two-Step test should be used forGDMscreen-
ing, we identified very limited evidence regarding whether
treatment of women meeting criteria for GDM by IADPSG
criteria (One-Step test) but not by other less strict criteria
has an effect on adverse pregnancy outcomes compared to no
treatment. Moreover, in none of the included studies was the
study group with milder disease treated for GDM (positive
for IADPSG criteria, but negative for less stringent criteria).
We also found a large variety of different criteria (IADPSG,
WHO, NICE, CDA, and C&C) for screening for GDM used
in the literature. Therefore, it is not surprising that societies
such as IADPSG, WHO, and FIGO recommend the One-
Step approach (assuming that identification of women with
milder GDMmight have benefits for them and their babies),
while others such as ACOG still recommend the Two-Step
approach for screening.
Only well designed RCTs comparing the One-Step versus
the Two-Step approach including huge populations could
answer this question.
4. Management Controversies
The aim of management is to reduce the risk of adverse
outcomes for the mother and the fetus. Several studies
demonstrated that treatment can be effective in reducing
adverse outcomes in GDM patients.
Regarding the effect of management on obstetrical out-
comes, there are many variables that can play a role; these
include
(i) criteria to start therapy after diet alone: once GDM
has been diagnosed, patients start nonpharmacologi-
cal therapy, that is, well balanced diet based on BMI
and physical exercise, but it is unclear how long
this evaluation period should last before deciding to
start pharmacological treatment; a recent systematic
review found inconclusive evidence for the threshold
value to start medical therapy [4];
(ii) type of initial therapy: insulin and oral hypoglycemic
agents are equally effective and can be used as first-
line therapy [5];
(iii) dose and frequency of initial therapy: therapy should
start at the lower effective dose and then increase
based on glucose monitoring;
(iv) frequency of glucose monitoring: when patients start
therapy, either diet or pharmacological therapy is
important to establish whether glycemic control has
been reached; while patients in pharmacological ther-
apy should perform glycemic checks at least four
times daily (fasting and after 1 or 2 hours from
threemainmeals: breakfast, lunch, and dinner), there
BioMed Research International 5
Table 4: Prospective non-RCTs or retrospective studies comparing incidence of GDM and/or outcomes between the One-Step and Two-Step
methods.
Author (origin) Study design Two-Step group One-Step group GDM rate Primary outcome
Duran et al., 2014
(Spain) [22]
Retroprospective
cohort
ACOG: 50 g 1 h
GCT; if >140mg/dL
followed by 100 g 3 h
GTT (C&C)
IADPSG: 75 g 2 h
GTT 10.6% versus 35.5% Pregnancy outcomes
Fuller and Borgida,
2014 (USA) [23]
Retroprospective
cohort
ACOG: 50 g 1 h
GCT; if >135mg/dL
followed by 100 g 3 h
GTT (C&C)
IADPSG: 75 g 2 h
GTT 7.0% versus 11.7%
Maternal and
delivery outcomes
Liu et al., 2014
(China) [24] Retrospective cohort
ACOG: 50 g 1 h
GCT; if >140mg/dL
followed by 100 g 3 h
GTT (C&C)
IADPSG: 75 g 2 h
GTT 7.0% versus 20.4%
Maternal and
perinatal outcomes
Oriot et al., 2014
(Belgium) [25] Retrospective cohort
ACOG: 50 g 1 h
GCT; if >140mg/dL
followed by 100 g 3 h
GTT (C&C)
IADPSG: 75 g 2 h
GTT 8.0% versus 23.0% CS, macrosomia
Wei et al., 2014
(China) [26] Retrospective cohort
ACOG: 50 g 1 h
GCT; if >135mg/dL
followed by 75 g 3 h
GTT (NDDG)
IADPSG: 75 g 2 h
GTT 18.3% versus 21.0% CS, macrosomia
Hung and Hsieh,
2015 (Taiwan) [27] Retrospective cohort
ACOG: 50 g 1 h
GCT; if >140mg/dL
followed by 100 g 3 h
GTT (C&C)
IADPSG: 75 g 2 h
GTT 4.6% versus 12.4% Macrosomia, LGA
Kong et al., 2015
(Canada) [28] Retrospective cohort
ACOG: 50 g 1 h
GCT; if >140mg/dL
followed by 100 g 3 h
GTT (C&C)
IADPSG: 75 g 2 h
GTT 7.9% versus 9.4%
Maternal and fetal
outcomes
Assaf-Balut et al.,
2016 (Spain) [29] Retrospective cohort
ADA: 50 g 1 h GCT;
if >140mg/dL
followed by 100 g 3 h
GTT (C&C)
IADPSG: 75 g 2 h
GTT Not stated
Postpartum
disorders
Klara Feldman et al.,
2016 (USA) [30]
Retroprospective
cohort
ACOG: 50 g 1 h
GCT; if >130mg/dL
followed by 100 g 3 h
GTT (C&C)
IADPSG: 75 g 2 h
GTT if HbA1c <
5.7%
17.0% versus 27.0% Pregnancy outcomes
is uncertainty for women in nonpharmacological
therapy [5];
(v) target glucose values: RCTs to identify ideal glycemic
targets have not been performed, but ADA and
ACOGrecommend a threshold of 140mg/dL at 1 hour
postprandially or 120mg/dL at 2 hours postprandially
as glycemic targets to reduce the risk of macrosomia
[5, 9];
(vi) criteria for pharmacologic therapy dose adjustment:
when choosing between tight versus very tight
glycemic control, we have to consider risk of hypo-
glycemia, effects of non-well-controlled GDM, and
women compliance;
(vii) criteria for adding or switching pharmacologic ther-
apy;
(viii) fetal monitoring;
(ix) time to delivery: women with GDM with good
glycemic control and no other complications can
be managed expectantly, while if GDM is not well
controlled with therapy, induction of delivery could
be considered [5].
We analyzed the literature to figure out which manage-
ment is the best to follow. When evaluating RCTs [16, 17,
39–51] which included criteria for starting pharmacologic
therapy in women with GDM, the most common frequency
for glucose monitoring was four times per day (i.e., when
fasting and after each main meal). The effect of therapy
on GDM was assessed using fasting of 90 (or 95)mg/dL
and 2 hours of 120mg/dL as blood glucose target values.
Importantly, we found several different criteria for starting
pharmacologic therapy after a period of diet alone, with the
majority using very tight criteria of either 1 or 2 values in one-
or two-week period higher than the target values, of which
6 BioMed Research International
Table 5: Prospective non-RCT or retrospective studies reporting outcomes of women meeting criteria for GDM based on the One-Step test
but not on the Two-Step test.
Author (origin) Study design GDM screening 50 g GCT criteria 75 g OGTT criteria 100 g OGTT criteria
Lapolla et al., 2011
(Italy) [31] Retrospective cohort
Two-Step: 50 g 1 h; if
>140mg/dL: 100 g
3 h GTT
≥140mg/dL: 100 g
3 h GTT Not done
2 abnormal values of
fasting ≥ 95mg/dL,
or
1 h 180mg/dl; 2 h
155mg/dL;
3 h 140mg/dL
Bodmer-Roy et al.,
2012 (Canada) [32] Retrospective cohort
Two-Step: 50 g 1 h; if
137–184mg/dL: 75 g
2 h GTT
137–184mg/dL: 75 g
GTT;
>184mg/dL: GDM
1 abnormal value of
fasting ≥ 96mg/dL;
1 h: ≥191mg/dl; 2 h:
≥160mg/dL∗
Not done
Benhalima et al.,
2013 (Belgium) [33] Retrospective cohort
Two-Step: 50 g 1 h; if
≥140mg/dL:100 g 3 h
GTT
≥140mg/dL: 100 g
3 h GTT Not done
2 abnormal values of
fasting ≥ 95mg/dL,
or
1 h 180mg/dl; 2 h
155mg/dL;
3 h 140mg/dL
Ethridge et al., 2014
(USA) [34] Retrospective cohort
Two-Step: 50 g 1 h; if
≥135mg/dL:100 g 3 h
GTT
≥135mg/dL: 100 g
3 h GTT Not done
2 abnormal values of
fasting ≥ 95mg/dL,
or
1 h 180mg/dl; 2 h
155mg/dL;
3 h 140mg/dL
Liao et al., 2014
(China) [35] Retrospective cohort
Two-Step: 50 g 1 h; if
≥140mg/dL: 100 g
3 h GTT
≥140mg/dL: 100 g
3 h GTT Not done
2 abnormal values of
fasting ≥ 95mg/dL,
or 1 h 180mg/dl; 2 h
155mg/dL;
3 h 140mg/dL
Mayo et al., 2015
(Canada) [36] Retrospective cohort
Two-Step: 50 g 1 h;
if 140–184mg/dL:
75 g 2 h GTT
If 140–184mg/dL:
75 g GTT;
>184mg/dL: GDM
1 abnormal value of
fasting ≥ 95mg/dL;
1 h: ≥191mg/dl: 2 h:
≥160mg/dL∗
Not done
Meek et al., 2015
(UK) [37] Retrospective cohort
Two-Step: 50 g 1 h;
if >138mg/dL: 75 g
2 h GTT
>138mg/dL: 75 g 2 h
GTT
1 abnormal value of
fasting ≥
110/128mg/dL; 2 h:
≥140mg/dL∗∗
Not done
Tward et al., 2016
(Canada) [38] Retrospective cohort
Two-Step: 50 g 1 h; if
>140mg/dL: 75 g 2 h
GTT
≥140mg/dL: 75 g 2 h
GTT
2 abnormal values of
fasting ≥ 95mg/dL;
1 h: ≥191mg/dl: 2 h:
≥160mg/dL
Not done
∗
2008 Canadian Diabetes Association criteria (ref.). ∗∗WHO 1999 criteria until 2007 (fasting, 148mg/dL), modified WHO 1999 criteria (fasting, 130mg/dL).
half used only 1 value and half used 2 values, while any RCT
used less tight criteria (i.e., >50% glucose values higher than
target values) (Table 7) [16, 17, 39–51].
Finally, when analyzing international organizations guide-
lines onmanagement of GDM,while there is consensus about
glycemic targets, we found different opinions about therapy,
monitoring, and time of delivery (Table 8). Moreover, there is
limited information regarding other important criteria about
dose and frequency of therapy, dose adjustment, and adding
or switching pharmacologic therapy.
Moreover, the application of the IADPSG was associated
with an increase in GDM prevalence up to 3.5-fold, as well
as significant improvements in pregnancy outcomes (gesta-
tional hypertension, prematurity, CD, number of LGA and
SGA, and 1-minute Apgar scores <7), and was cost-effective.
This could be presumably by permitting the treatment of a
greater number ofwomen at risk for pregnancy complications
[22].
5. Conclusion
There are many unsolved questions concerning GDM man-
agement. Analyzing the literature in detail, we found differ-
ent criteria for screening for GDM, for monitoring GDM,
and for starting pharmacological therapy. The hope is to
reach universally approved and shared recommendations to
improve health care and reduce costs and adverse outcomes
for women with GDM and their babies.
BioMed Research International 7
Table 6: Continues on the same studies as in Table 5.
Author (origin) Study group Control Primary outcome
Lapolla et al., 2011 (Italy) [31]
100 g IADPSG-positive,
C&C-negative
(fasting: 92–94mg/dL; 2 h:
153-154mg/dL; not treated)
[𝑛 = 112]
IADPSG-negative
(fasting: <92mg/dL; 1 h:
<180mg/dL; 2 h:
<153mg/dL)
[𝑛 = 1815]
Perinatal outcomes
Bodmer-Roy et al., 2012
(Canada) [32]
75 g IADPSG-positive,
CDA-negative
(fasting: 92–95mg/dL; 1 h:
180–190mg/dL; 2 h:
153–159mg/dL; not treated)
[𝑛 = 186]
GCT-negative (50 g 1 h <
137mg/dL)
[𝑛 = 186]
Or
IADPSG-negative
(fasting: <92mg/dL; 1 h:
<180mg/dL; 2 h:
<153mg/dL)
[𝑛 = 186]
LGA > 90th percentile
Benhalima et al., 2013
(Belgium) [33]
100 g IADPSG-positive,
C&C-negative
(fasting: 92–94mg/dL; 2 h:
153-154mg/dL; not treated)
[𝑛 = 160]
GCT-negative (50 g 1 h <
140mg/dL)
And
IADPSG-negative
(fasting: <92mg/dL; 1 h:
<180mg/dL; 2 h:
<153mg/dL)
[𝑛 = 6345]
Pregnancy outcomes
Ethridge et al., 2014 (USA)
[34]
100 g IADPSG-positive,
C&C-negative
(fasting: 92–94mg/dL; 2 h:
153-154mg/dL; not treated)
[𝑛 = 281]
GCT-negative (50 g 1 h <
135mg/dL)
[𝑛 = 6999]
Or
IADPSG-negative
(fasting: <92mg/dL; 1 h:
<180mg/dL; 2 h:
<153mg/dL)
[𝑛 = 772]
Birth weight and neonatal
outcomes
Liao et al., 2014 (China) [35]
100 g IADPSG-positive,
C&C-negative
(fasting: 92–94mg/dL; 2 h:
153-154mg/dL; not treated)
[𝑛 = 1314]
GCT-negative (50 g 1 h <
140mg/dL)
And
IADPSG-negative
(fasting: <92mg/dL; 1 h:
<180mg/dL; 2 h:
<153mg/dL)
[𝑛 = 2662]
Maternal and neonatal
outcomes
Mayo et al., 2015 (Canada)
[36]
75 g IADPSG-positive,
CDA-negative
(fasting: 92–95mg/dL; 1 h:
180–190mg/dL; 2 h:
153–159mg/dL; not treated)
[𝑛 = 155]
GCT-negative
(50 g 1 h < 140mg/dL)
[𝑛 = 4183]
Or
IADPSG-negative
(fasting: <92 mg/dL; 1 h:
<180 mg/dL; 2 h: <153
mg/dL)
[𝑛 = 526]
Not stated
Meek et al., 2015 (USA) [37]
75 g IADPSG-positive,
NICE-negative
(fasting: 92–101mg/dL; 1 h:
≥153mg/dL; not treated)
[𝑛 = 387]
IADPSG-negative
(fasting: <92mg/dL; 1 h:
<180mg/dL; 2 h:
<153mg/dL)
[𝑛 = 2406]
Delivery and neonatal
outcomes
Tward et al., 2016 (Canada)
[38]
75 g IADPSG-positive,
CDA-negative
(fasting: 92–95mg/dL; 1 h:
180–190mg/dL; 2 h:
153–159mg/dL; not treated)
[𝑛 = 99]
GCT-negative
(50 g 1 h < 140mg/dL)
[𝑛 = 1021]
Or
IADPSG-negative
(fasting: <92mg/dL; 1 h:
<180mg/dL; 2 h:
<153mg/dL)
[𝑛 = 184]
Fetal growth in twins
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Table 7: Management of women included in RCTs.
Glucose monitoring Target value forglycemic control Type of diet
Recommendations
about exercise
Glucose values used
for starting
pharmacologic
therapy based on
target values
Garner et al., 1997
[39] 4 times daily
A
F: <4.4mmol/l
(80mg/dL);
1 h: <7.8mmol/l
(140mg/dL)
35 kcal/kg IBW/day Not stated 2 or more valueshigher in 2 weeks
Langer et al., 2000
[40] 7 times daily
B
F: <5.0mmol/l
(90mg/dL);
preprandial:
<5.3mmol/l
(95mg/dl)
2 h: <6.7mmol/l
(120mg/dL)
(i) 25 kcal/kg
BW/day for obese
women
(ii) 35 kcal/kg
BW/day for
nonobese women
(iii) 3 meals and 4
snacks
(iv) 40–45% of
calories from
carbohydrates
Not stated
1 or more
preprandial or 2 h
values higher in 1
week
Mecacci et al., 2003
[41] 9 times daily
C
F: <5.0mmol/l
(90mg/dL);
1 h: <6.7mmol/l
(120mg/dL)
ADA
recommendations∗ Not stated
More than 50%
values higher after 1
week
Schaefer-Graf et al.,
2004 [42] 6 times daily
D
Intervention group:
F: <4.5mmol/l
(80mg/dL);
1 h: <6.1mmol/l
(110mg/dL)
Control group:
F: <5.0mmol/l
(90mg/dL);
1 h: <6.7mmol/l
(120mg/dL)
(i) 25 kcal/kg
BW/day for
overweight women
(ii) 30 kcal/kg
BW/day for normal
weight women
Exercise after meals
Intervention group:
(i) AC > 75th 𝑝 < 36
weeks
(ii) F ≥ 120mg/dL
(iii) 2 h ≥ 200mg/dL
Control group:
(iv) 2 or more values
(v) 4 profiles with at
least 1 value higher
in 2 weeks
Crowther et al., 2005
[16] 4 times daily
E
F: <5.5mmol/l
(99mg/dL);
2 h: <7.0mmol/l
(126mg/dL)
Dietary advice from
a qualified dietician Not stated
(i) 2 values higher in
2 weeks <35 weeks
(ii) 2 h >8.0mmol/l
(144mg/dl) in 2
weeks >35 weeks
(iii) 1 value
>9.0mmol/l
(162mg/dl) in 2
weeks
Anjalakshi et al.,
2007 [43] Not specified
2 h: <6.7mmol/l
(120mg/dL)
Medical Nutrition
Therapy (MNT) Not stated
1 value 2 h higher in
2 weeks
Landon et al., 2009
[17] 4 times daily
E
F: <5.3mmol/l
(95mg/dL);
2 h: <6.7mmol/l
(120mg/dL)
ADA
recommendations∗∗ Not stated
(i) >50% values
higher between 2
study visits
(ii) 1 random value
>160mg/dl
(8.9mmol/l)
(iii) 1 F > 95mg/dl;
the patient’s
caregiver initiated
treatment (more or
less 7 visits)
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Table 7: Continued.
Glucose monitoring Target value forglycemic control Type of diet
Recommendations
about exercise
Glucose values used
for starting
pharmacologic
therapy based on
target values
Ija¨s et al., 2011 [44] 4 times dailyF
F: <5.3 mmol/l
(95mg/dL);
1.5 h: <6.7mmol/l
(120mg/dL)
Dietary and lifestyle
counselling
Not stated 2 values higher in
2–4 weeks
Balaji et al., 2012 [45] 4 times dailyE
F: <5.0mmol/l
(90mg/dL);
2 h: <6.7mmol/l
(120mg/dL);
HbA1c: <6.0 g/dL
Medical Nutrition
Therapy (MNT) Not stated
1 value higher in 2
weeks
Mukhopadhyay et
al., 2012 [46] 7 times daily
B
F: <5.0mmol/l
(90mg/dL);
2 h: <6.7mmol/l
(120mg/dL)
(i) 25 kcal/kg BW for
obese women
(ii) 35 kcal/kg BW
for nonobese
women
(iii) 3 daily meals;
40–45% of calories
from carbohydrates
Not stated 1 value higher in 2weeks
Niromanesh et al.,
2012 [47] 4 times daily
E
F: <5.3mmol/l
(95mg/dL);
2 h: <6.7mmol/l
(120mg/dL)
(i) 15 kcal/kg BW for
obese women
(ii) 22 kcal/kg BW
for overweight
women
(iii) 30 kcal/kg BW
for normal weight
women
(iv) 40 kcal/kg BW
for underweight
women
(v) 45% of calories
from carbohydrates,
20% from protein,
and 35% from fat
(vi) 3 meals and 3
snacks
(vii) Calories: 10%
breakfast, 30% each
lunch and dinner,
and 30% snacks
30 minutes of
walking per day
2 values higher in
one week
Silva et al., 2010 [48] 4 times dailyA
F: <5.0mmol/l
(90mg/dL);
1 h: <6.7mmol/l
(120mg/dL)
(i) 25 kcal/kg
BW/day for
overweight women
(ii) 35 kcal/kg
BW/day for normal
weight women
(iii) 3 full meals and
4 light meals
(iv) 35–45% of
calories from
carbohydrates
Not stated 2 values higher after1 week
Mesdaghinia et al.,
2013 [49] 4 times daily
E
F: <5.3mmol/l
(95mg/dL);
2 h: <6.7mmol/l
(120mg/dL)
Dietary changes∗∗∗ Not stated 1 value higher in 1week
Spaulonci et al., 2013
[50] 4 times daily
E
F: <5.3mmol/l
(95mg/dL);
2 h: <6.7mmol/l
(120mg/dL)
(i) 25–35 kcal/kg
IBW based on
pregestational BMI
(ii) 55%
carbohydrates, 15%
proteins, and 30% fat
30-minute walk 3
times a week
>30% values higher
in 1 week
10 BioMed Research International
Table 7: Continued.
Glucose monitoring Target value forglycemic control Type of diet
Recommendations
about exercise
Glucose values used
for starting
pharmacologic
therapy based on
target values
Behrashi et al., 2016
[53] 4 times daily
E
F: <5.0mmol/l
(90mg/dL);
2 h: <6.7mmol/l
(120mg/dL)
Education for
lifestyle change
(exercise and diet)
Education for
lifestyle change
(exercise and diet)
1 value higher in 1
week
F: fasting; GA: gestational age; IBW: ideal body weight; BW: body weight; BMI: body mass index.
AFasting and 1 hour after each main meal: breakfast, lunch, and dinner.
BFasting, before lunch and dinner, 2 hours after main meals, breakfast, lunch, and dinner, and at bedtime.
CFasting, preprandial before lunch and dinner, 1 and 2 hours after each main meal: breakfast, lunch, and dinner.
DFasting, preprandial before lunch and dinner, 1 hour after each main meal: breakfast, lunch, and dinner.
EFasting and 2 hours after each main meal: breakfast, lunch, and dinner.
FFasting and 1.5 hours after each main meal: breakfast, lunch, and dinner.
∗American Diabetes Association, Medical Management of Pregnancy Complicated by Diabetes, 3rd Edition, Alexandria, Virginia; ADA, 2000, pp. 70–86.
∗∗American Diabetes Association, Nutrition Recommendations and Interventions for Diabetes: A Position Statement of the American Diabetes Association;
Diabetes Care 2008 Jan. 31 (Suppl. 1): S61–S78.
∗∗∗Cheung NW,The Management of Gestational Diabetes: A Review Article; Vasc Health Risk Manag. 2009; 5:153–64.
Table 8: Management of GDM, international guidelines.
ACOG 2013 [4] CDA 2013 [10] ADA 2015 [9] FIGO 2015 [5] NICE 2015 [11]
Criteria to start
therapy after diet
alone
Inconclusive
evidence
Glycemic control
not achieved after 2
weeks of nutritional
therapy alone
NR NR
Glycemic control
not achieved after
1-2 weeks of diet and
exercise
Type of initial
therapy
Insulin or oral
medications
Insulin or oral
medications Insulin or glyburide
Glyburide inferior to
both insulin and
metformin,
while metformin
performs
better than insulin
Metformin
Dose and frequency
of initial therapy NR NR NR NR NR
Frequency of glucose
monitoring
4 times
daily as fasting
and either 1 h or 2 h
after each meal
4 times
daily as fasting
and either 1 h or 2 h
after each meal
NR
4 times
daily as fasting
and 2 h after each
meal
7 times
daily as fasting,
premeal, 1 h after
each meal, bedtime
Target glucose values 1 h ≤ 140mg/dL,2 h ≤ 120mg/dL
Fasting ≤ 95mg/dL,
1 h ≤ 140mg/dL,
2 h ≤ 120mg/dL
Fasting ≤ 95 mg/dL,
1 h ≤ 140mg/dL,
2 h ≤ 120mg/dL
Fasting ≤ 95mg/dL,
1 h ≤ 140mg/dL,
2 h ≤ 120mg/dL
Fasting ≤ 95mg/dL,
1 h ≤ 140mg/dL,
2 h ≤ 116mg/dL
Criteria for
pharmacologic
therapy dose
adjustment
NR NR NR NR NR
Criteria for adding or
switching
pharmacologic
therapy
NR NR NR NR NR
Pregnancy
monitoring No consensus NR NR NR
Ultrasound
monitoring of fetal
growth and
AF volume every 4
weeks from 28 to 36
weeks
Time to delivery
Well-controlled: >39
weeks; insufficient
data for others; CD
if EFW > 4500 g
NR NR Consider inductionat 38-39 weeks
Delivery no later
than 40 + 6 weeks
NR: not reported.
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